Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

80% Of Canadians Want Airlines To Offer Pet-Free Flights: Lung Association Poll
Eighty percent of Canadians believe Canada"s airlines should offer some pet-free flights to protect the health and safety of passengers and crew members, according to a new survey released today by The Canadian Lung Association. The findings come as Air Canada prepares to join WestJet in allowing pets to travel in the passenger cabin of airplanes - pet allergens can trigger serious or even life-threatening reactions in people with lung diseases like asthma and COPD.

Obstructive Sleep Apnea Prevalent In Nonobese Patients
There is a high probability of obstructive sleep apnea (OSA) in non-obese, middle-aged patients, according to a research abstract presented at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies.
News of the day
Women With Gestational Diabetes During Pregnancy Have A Substantial And Persistently Elevated Risk Of Type 2 Diabetes Post-Birth
Women who develop gestational diabetes (GD) during pregnancy have a seven-and-a-half times increased risk of developing type 2 diabetes post-birth, which lasts throughout their lifetime. However, there is no agreed policy on the long-term follow up of these women and many do not return for the currently recommended 6-week post-birth diabetes check. An Article in this week"s diabetes special issue of The Lancet says that the strength of the association suggests that both disorders have an overlapping cause-and this should act as an incentive for women to attend the recommended post-birth check. This attendance could be an opportunity to provide advice on diet and exercise, and treatments to delay or prevent onset of diabetes-as well as alerting these women to symptoms of future diabetes, and to alert general practitioners responsible for their long-term care.
Public Health

New Treatment Option For Patients With Chronic Hepatitis C

A new combination therapy of daily consensus interferon (CIFN) and ribavirin is effective for some people with chronic hepatitis C (HCV) who do not respond to standard therapy. The treatment works particularly well in interferon-sensitive patients who have lower fibrosis scores, according to a new study in the June issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The article is also available online at Wiley Interscience. Nearly half of all HCV patients do not respond to the standard therapy of pegylated interferon and ribavirin. They remain at risk for developing life-threatening liver disease. So far, other alternative therapies have not been particularly successful in these nonresponders. One new treatment with the potential to help patients with persistent HCV involves high doses of daily consensus interferon (CIFN) combined with ribavirin. Researchers, led by Bruce Bacon of St. Louis University, conducted a multicenter trial to examine the efficacy, tolerability and safety of this approach. The researchers studied 487 patients whose HCV had not responded to initial treatment with standard therapy. Many had characteristics that generally bode poorly for treatment response. Nearly all had HCV genotype 1; 80 percent had not responded strongly to their previous treatment; 68 percent had high baseline levels of the virus in their blood; 60 percent had advanced liver disease; and about 20 percent were African-American. These factors have all been shown to reduce rates of sustained viral response after treatment. The patients were divided into three groups. Two would receive the new therapy at different doses, and the third would receive no therapy. After 24 weeks, the control group was stratified into one of the treatment arms. Ultimately, 245 of the patients received 9 mcg of CIFN daily along with ribavirin, and 242 others took 15 mcg of CIFN daily along with ribavirin. After 24 weeks, patients with detectable HCV RNA were considered non-responders and stopped the therapy. Responders continued taking their therapy up through week 48, and were then followed-up through week 72. If HCV RNA was detected between weeks 48 and 72, the patient was classified as a relapser. Nearly 7 percent of the patients taking 9 mcg of CIBN, and 10.7 percent of those taking 15 mcg, achieved a sustained viral response. The rates were even higher among patients who had responded better to the standard therapy and among those who had lower baseline fibrosis scores. "The best response rate, 31.6 percent, was observed in noncirrhotic patients who had a partial virologic response with a greater than 2-log10 decline in HCV RNA during their previous course of peg-IFN treatment," the authors report. While adverse events were common, most patients continued their treatment in spite of them. Common side effects were neutropenia, fatigue, leucopenia, depression, nausea, muscle pain, lymphopenia and anemia. "The present study demonstrated that some patients with chronic hepatitis C who have failed to respond to treatment with peg-IFN and RBV can be successfully retreated with daily CIFN and RBV," the authors conclude. "The greatest SVR rate during retreatment in the present study was observed in F0-F3 patients who had a partial virologic response during their prior course of treatment." Article: "Retreating Chronic Hepatitis C with Daily Interferon Alfacon-1/Ribavirin after Nonresponse to Pegylated Interferon/Ribavirin: DIRECT Results." Bacon, Bruce R.; Shiffman, Mitchell; Mendes, Flavia; Ghalib, Reem; Hassanein, Tarek; Morelli, Giuseppe; Joshi, Shobha; Rothstein, Kenneth; Kwo, Paul; Gitlin, Norman. Hepatology; June 2009. Sean Wagner Wiley-Blackwell


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009